See more : Gefen International A.I. Ltd (GFN.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Synaptogenix, Inc. (SNPX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Synaptogenix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Harrisons Malayalam Limited (HARRMALAYA.NS) Income Statement Analysis – Financial Results
- Equitable Holdings, Inc. (AXJ.DE) Income Statement Analysis – Financial Results
- Mitsui Mining & Smelting Co., Ltd. (MMSMY) Income Statement Analysis – Financial Results
- Inwido AB (publ) (INWI.ST) Income Statement Analysis – Financial Results
- Nel ASA (D7G.F) Income Statement Analysis – Financial Results
Synaptogenix, Inc. (SNPX)
About Synaptogenix, Inc.
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.35K | 5.71K | 4.97K | 4.87K | 4.39K | 3.00K |
| Gross Profit | -6.35K | -5.71K | -4.97K | -4.87K | -4.39K | -3.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.97M | 6.32M | 4.34M | 3.07M | 5.67M | 4.89M |
| General & Administrative | 6.34M | 9.81M | 8.28M | 8.09M | 9.84M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.34M | 9.81M | 8.28M | 8.09M | 9.84M | 6.26M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 28.36K | 0.00 | 0.00 |
| Operating Expenses | 8.31M | 16.13M | 12.62M | 11.16M | 15.51M | 11.15M |
| Cost & Expenses | 8.31M | 16.13M | 12.62M | 11.16M | 15.51M | 11.15M |
| Interest Income | 1.65M | 335.04K | 7.11K | 153.21K | 378.71K | 127.11K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.35K | 5.71K | 4.97K | 4.87K | 4.39K | 3.00K |
| EBITDA | -8.31M | -16.13M | -12.61M | -11.15M | -15.51M | -11.02M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.31M | -26.36M | -12.62M | -9.46M | -15.51M | -11.15M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.28M | 10.56M | 7.11K | -1.55M | 378.71K | 127.11K |
| Income Before Tax | -6.04M | -5.57M | -12.61M | -12.70M | -15.13M | -11.02M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -115.89K | -7.11K | 1.55M | -378.71K | 1.00 |
| Net Income | -6.04M | -5.46M | -12.60M | -14.25M | -14.76M | -11.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -29.56 | -0.78 | -2.51 | -11.33 | -2.48 | -46.33 |
| EPS Diluted | -29.56 | -0.78 | -2.51 | -11.33 | -2.48 | -46.33 |
| Weighted Avg Shares Out | 466.08K | 6.99M | 5.02M | 1.26M | 5.95M | 237.91K |
| Weighted Avg Shares Out (Dil) | 466.08K | 6.99M | 5.02M | 1.26M | 5.95M | 237.91K |
Synaptogenix Announces $5.0 Million Financing
NEW YORK , Sept. 11, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0...
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in the treatment of neurodegenerative diseases NEW YORK , July 18, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an...
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery
Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways NEW YORK , May 7, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders,...
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
NEW YORK , April 24, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22, 2024, informing the...
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing
Common stock will begin trading on split-adjusted basis on April 5, 2024 NEW YORK , April 3, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that...
Synaptogenix President Daniel L. Alkon, M.D.
Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK , Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics...
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's
Presenters, including Nobel Laureate in Medicine, to discuss innovative treatments for neurodegeneration Company to feature lead therapeutic's statistically significant benefits, p < 0.007, for severe Alzheimer's disease (AD) patients NEW YORK , Dec. 6, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq:...
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology
Acquires 25% stake in Cannasoul Analytics for up to $4 million to support R&D for cannabinoid- and psilocybin mushroom-based therapeutics for multiple indications Partners to drive development and commercialization of Cannasoul Analytics' intellectual property and technologies licensed from The Technion...
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease
Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK , Sept. 26, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for...
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
Let's be honest – penny stocks priced at less than a buck hold an irresistible appeal. Even a small investment could potentially lead to insane returns.
Source: https://incomestatements.info
Category: Stock Reports